Crizotinib-associated erythema multiforme in a lung cancer patient
-
- Sawamura Soichiro
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University
-
- Kajihara Ikko
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University
-
- Ichihara Asako
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University
-
- Fukushima Satoshi
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University
-
- Jinnin Masatoshi
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University
-
- Yamaguchi Emi
- Department of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University
-
- Kohrogi Hirotsugu
- Department of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University
-
- Ihn Hironobu
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University
Search this article
Abstract
Crizotinib is an oral small-molecule anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor for the treatment of ALK-positive non-small-cell lung cancer (NSCLC). A 63-year old woman with postoperative relapsed ALK-positive NSCLC was treated with crizotinib. Erythema multiforme (EM) occurred one week after initiation of crizotinib therapy. Skin biopsy specimen showed compatible drug eruption. The discontinuation of crizotinib improved her eruption within one week. This report presented the first case of crizotinib-associated EM, which is the preclinical stage of Stevens-Johnson syndrome. Although crizotinib is clinically available, we should be aware of its potential severe skin adverse event.
Journal
-
- Drug Discoveries & Therapeutics
-
Drug Discoveries & Therapeutics 9 (2), 142-143, 2015
International Research and Cooperation Association for Bio & Socio-Sciences Advancement